Key figures — Lumpectomy vs mastectomy
Medical statistics for quick understanding.
When facing a diagnosis of breast cancer, choosing between lumpectomy and mastectomy is one of the most important decisions to make with your surgical team. Both procedures offer equivalent overall survival — the right choice depends on your tumour profile, your anatomy, and your personal preferences.
For a full overview of surgical management, see our page on breast cancer surgery.
Understanding the two procedures
Before either operation is considered, diagnosis and staging rely on imaging and tissue analysis: the mammogram, sometimes complemented by a breast MRI, then a breast biopsy that confirms the diagnosis and details the tumour's characteristics. These findings guide the choice between breast-conserving treatment and mastectomy.
Lumpectomy: breast-conserving surgery
A lumpectomy removes only the tumour and a margin of healthy tissue, preserving most of the breast. The procedure takes between 30 minutes and 1h15 depending on tumour size and whether an oncoplastic technique is used. An intraoperative pathological analysis may verify clear margins.
- Breast conservation — natural shape preserved
- Fast recovery — return to activities in 1–2 weeks
- Radiotherapy required — 3–5 weeks in the vast majority of cases
- Lifelong surveillance — annual mammogram ± ultrasound ± MRI
- Risk of re-excision — 10–15% of cases if margins are involved
Mastectomy: complete removal of the breast gland
Mastectomy is always total — the entire breast gland is removed. What varies is the decision to reconstruct or not, and if so, how.
Option 1 — Flat closure (no reconstruction)
The breast gland is removed without volume reconstruction. Some patients deliberately choose this option for personal, medical or practical reasons. An external prosthesis can be worn if desired.
Option 2 — Immediate breast reconstruction (IBR)
Reconstruction is performed during the same procedure as the mastectomy. Two main strategies:
- NAC-preserving (nipple-areola complex) — possible when the tumour is far from the nipple. Inframammary or axillary incision.
- NAC-sacrificing — central oblique scar. Nipple reconstruction possible later.
Volume is restored by:
- Implant — definitive prosthesis or tissue expander (learn more)
- Fat grafting (lipofilling) — autologous fat injection (learn more)
- Autologous flaps — DIEP, latissimus dorsi (learn more)
Operating time: 2 to 5 hours depending on technique and reconstruction.
How to choose?
Factors favouring lumpectomy
- Single small tumour adapted to breast volume
- Favourable tumour-to-breast ratio for a good cosmetic result
- No contraindication to radiotherapy
- Clear margins achievable
When removal is needed
Large or multifocal tumour, local recurrence, contraindication to radiotherapy, BRCA mutation, or personal choice after full information: situations where mastectomy becomes the safer option.
Factors favouring mastectomy
- Large tumour compromising cosmetic outcome
- Multifocal or multicentric disease
- Extensive DCIS
- Contraindication to radiotherapy (e.g. previous thoracic irradiation)
- BRCA1/BRCA2 mutation — discussion of contralateral prophylactic mastectomy
- Local recurrence after prior lumpectomy and radiotherapy
Key point: Randomised studies (Veronesi, Fisher — NEJM 2002) have not demonstrated any difference in long-term overall survival between lumpectomy followed by radiotherapy and mastectomy. The choice is based on tumour, anatomical and personal criteria — not oncological superiority of one technique.
Personal and psychological factors
Beyond medical criteria, your feelings matter. Some patients prefer to preserve their breast; others wish to minimise anxiety about recurrence. These preferences are legitimate and should be discussed at your consultation.
- Body image — importance placed on breast preservation
- Fear of recurrence — tolerance of residual risk
- Access to radiotherapy — geographical or professional constraints
- Reconstruction plans — desire, timing, feasibility
MDT: a collegial view
Every decision goes through MDT — multidisciplinary team meeting. Surgeon, oncologist, radiotherapist, radiologist and pathologist together validate the strategy proposed to you.
Special situations
- Young women (< 40) — systematic oncogenetic evaluation recommended
- Pregnancy — surgery possible, radiotherapy delayed until after delivery
- Inflammatory breast cancer — mastectomy after neoadjuvant chemotherapy; formal contraindication to immediate reconstruction
- Recurrence after lumpectomy — mastectomy indicated; re-irradiation is contraindicated
- BRCA1/BRCA2 mutations — bilateral prophylactic mastectomy to be discussed
- Low-risk ductal carcinoma in situ (DCIS) — surgery remains the standard of care. An active monitoring strategy (no upfront surgery) is being evaluated in the COMET trial (JAMA, 2025) in selected patients, but it remains a research approach and does not, to date, change standard surgical management.
Need a specialist opinion on your surgical options?
Dr Zeitoun offers consultations to discuss lumpectomy vs mastectomy, in person at Paris 8th or Clinique Hartmann (Neuilly-sur-Seine).
Book an appointment →Recovery after each procedure
After lumpectomy: return to activities in 1–2 weeks. After mastectomy: 3–6 weeks depending on technique and reconstruction. In both cases, you are accompanied at each post-operative follow-up visit.
The sentinel lymph node & axillary dissection
Whether you have a lumpectomy or mastectomy, assessing the axilla is part of the surgical plan. The sentinel lymph node technique now makes it possible to evaluate the lymph nodes without removing the whole axilla — in the vast majority of cases. Learn about the technique, the procedure, the systematic compression sleeve after dissection, and the recent trials (Z0011, AMAROS, SENOMAC) that have transformed care.
Read the dedicated page →
Dr Jérémie Zeitoun
Surgical oncologist, breast and gynaecological surgeon. Former specialist practitioner at Institut Gustave Roussy. Practices at Paris 8th (241 rue du Faubourg Saint-Honoré) and Clinique Hartmann, Neuilly-sur-Seine..
Let's discuss your situation
A consultation allows precise assessment of your options. Dr Zeitoun offers prompt appointments in Paris or Neuilly-sur-Seine.
Lumpectomy vs mastectomy
Comparison of both surgical options for breast cancer.
| Criterion | Lumpectomy | Mastectomy |
|---|---|---|
| Breast preservation | Yes | No (unless reconstruction) |
| Radiotherapy | Mandatory | Depending on stage |
| 20-year overall survival | Equivalent (Veronesi 2002) | Equivalent (Veronesi 2002) |
| 10-year local recurrence | 5-10% | 2-5% |
| Reconstruction | N/A (oncoplasty possible) | Immediate or delayed |
| Scar | Small, periareolar or radial | Extensive, horizontal |
| Hospital stay | Day surgery or 1 night | 1-2 nights |
Source: Veronesi 2002 (NEJM), NSABP B-06 (Fisher 2002), EBCTCG meta-analysis.
Scientific bibliography
This article draws on guidelines from learned societies (ACOG, NICE, ESMO, NCCN, HAS, INCa) and on landmark peer-reviewed trials.
- Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy. N Engl J Med. 2002;347(16):1227-1232. PubMed 12393819.
- Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy with lumpectomy and radiation. N Engl J Med. 2002;347(16):1233-1241. PubMed 12393820.
- Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death. Lancet. 2011;378(9804):1707-1716. PubMed 22019144.
- Houssami N, Macaskill P, Marinovich ML, et al. Meta-analysis of the impact of surgical margins on local recurrence. Eur J Cancer. 2010;46(18):3219-3232. PubMed 20817513.
- NCCN. Clinical Practice Guidelines in Oncology - Breast Cancer. nccn.org.
- ESMO. Early Breast Cancer Clinical Practice Guidelines. Ann Oncol. 2019;30(8):1194-1220. PubMed 31161190.
- NICE. Early and locally advanced breast cancer: diagnosis and management (NG101). nice.org.uk.
- Haute Autorité de Santé (HAS). Cancer du sein - parcours de soins. has-sante.fr.
- Houssami N, Ciatto S, Macaskill P, et al. Accuracy and surgical impact of magnetic resonance imaging in breast cancer staging. J Clin Oncol. 2008;26(19):3248-3258. PMID: 18474876.
- Houssami N, Macaskill P, Marinovich ML, et al. Meta-analysis of the impact of surgical margins on local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy. Eur J Cancer. 2010;46(18):3219-3232. PMID: 20817513.
- Esserman LJ, Hylton NM, Asare SM, et al. I-SPY 2: Unlocking the Potential of the Platform Trial. Clin Pharmacol Ther. 2021;109(3):646-654. PMID: 33049068.
- Hwang ES, Hyslop T, Lynch T, et al. (COMET Study) Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ: The COMET Randomized Clinical Trial. JAMA. 2025;333(11):972-980. PMID: 39665585.
This article is for information only and does not replace an individual medical consultation.